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Diabetesisachronicmetabolicdisorder,characterizedbyhyperglycemiaresultingfrominsulindeﬁciencyand/orinsulinresistance.
Recent evidence suggests that high levels of reactive oxygen species (ROS) and subsequent oxidative stress are key contributors in
thedevelopmentofdiabeticcomplications.TheFOXOfamilyofforkheadtranscriptionfactorsincludingFOXO1,FOXO3,FOXO4,
and FOXO6 play important roles in the regulation of many cellular and biological processes and are critical regulators of cellular
oxidative stress response pathways. FOXO1 transcription factors can aﬀect a number of diﬀerent tissues including liver, retina,
bone, and cell types ranging from hepatocytes to microvascular endothelial cells and pericytes to osteoblasts. They are induced by
oxidativestressandcontributetoROS-inducedcelldamageandapoptosis.Inthispaper,wediscusstheroleofFOXOtranscription
factors in mediating oxidative stress-induced cellular response.
1.Introduction
Diabetes mellitus is a chronic disease characterized by ele-
vated blood sugar levels resulting from either lack of insulin
productionorresistancetoinsulin.In2010,therewerenearly
230 million individuals with diabetes worldwide which is
estimated to reach 430 million by 2030 [1]. Recently, a
study conducted by the U.S. Centers for Disease Control and
Prevention (CDC) indicated that 25.8 million Americans or
8.3% of its population were aﬀected by diabetes in 2010 [2].
Diabetes has severe health consequences associated with nu-
merous diabetic complications including retinopathy, neu-
ropathy, and nephropathy [3–5]. Accumulating evidence
suggests that hyperglycemia-induced production of free rad-
icals and the subsequent oxidative stress contributes to the
development and progression of diabetes and related com-
plications [6–8].
Reactive oxygen species (ROS) are oxygen free radicals
that are generated as by-products of mitochondrial metab-
olism and function as signaling molecules in various intra-
cellular processes including cell proliferation, migration, and
apoptosis [9]. ROS produced during normal metabolic proc-
esses are removed rapidly with the help of various endoge-
nous detoxifying enzymes. While normal cellular ROS
concentrations are necessary for proper functioning of cells,
excessive, non-physiological concentrations of ROS result in
o x i d a t i v es t r e s s .R O Ss u c ha ss u p e r o x i d e( O 2
−) and hydroxyl
radicals (HO￿), and hydrogen peroxide (H2O2), are highly
reactive and can cause damage to biological macromolecules
such as DNA, proteins, and lipids [9]. Major sources of
oxidative stress during diabetes include glucose autooxida-
tion, overproduction of ROS by mitochondria, non-enzy-
matic glycation, and the polyol pathway [6, 10]. In the polyol
pathway, aldose reductase converts glucose into sorbitol with
NADPH as a coenzyme. In diabetes, increased ﬂux through
the polyol pathway enhances oxidative stress because of in-
creased consumption of NADPH by aldose reductase. Since
NADPH is required for generation of endogenous antiox-
idant glutathione (GSH), reduced NADPH availability de-
pletes GSH leading to greater oxidative stress [6]. Other
mechanisms through which high glucose levels can lead to
advanced glycation endproducts are discussed below.
ROS leads to the generation of intracellular signals that
stimulate inﬂammation and cell death. They include protein
kinase C (PKC), c-Jun-N-terminal kinase (JNK), and p38
mitogen-activated protein kinase (MAPK) [11–15]. In many2 Experimental Diabetes Research
cell types, ROS lead to the activation of the forkhead box O
(FOXO) transcription factors that include FOXO1, FOXO3,
and FOXO4, which can mediate the eﬀects of ROS through
regulation of gene transcription. These transcription factors
have been implicated in diverse cellular processes ranging
from glucose metabolism to cell behavior including cell cycle
and apoptosis [16, 17]. In addition to being activated by
ROS, FOXO proteins play a critical role in oxidative stress by
upregulating expression of antioxidant genes [9]. However,
FOXO proteins are involved in many other processes and can
have apparently contradictory eﬀects in diﬀerent cell types
[18]. FOXO proteins are transcription factors but also have
important function as corepressors or coactivators so that
direct DNA binding is not a prerequisite for modulating the
transcription of gene targets [19]. For simplicity, we will use
the term FOXO for all or any of the FOXO transcription
factors throughout this paper, unless otherwise speciﬁed.
2. Regulation of FOXO by OxidativeStress
FOXO transcription factors are critical mediators of oxida-
tive stress and are activated by various kinds of cellular
stress stimulus. Oxidative stress regulates FOXO activity
through various posttranslational modiﬁcations including
phosphorylation, acetylation, and ubiquitination, which in
turn regulate the subcellular localization of FOXOs, protein-
protein interactions, and transcriptional activity of FOXO
proteins. While some of these modiﬁcations promote FOXO
transcriptional activity, others are inhibitory. For example,
stress-activated kinase JNK directly phosphorylates FOXO4
at residues Thr447 and Thr451, which leads to its nuclear
translocation and induces FOXO4 transcriptional activity
[20]. Another kinase implicated in oxidative stress-induced
phosphorylation of FOXO is mammalian Ste20-like protein
kinase 1 (MST1). During oxidative stress, MST1 phospho-
rylates FOXO3 at residue Ser207, which results in FOXO3
release from binding protein, 14-3-3. This release allows
FOXO3 to translocate to the nucleus thereby modulating
target gene expression [21].
FOXO transcriptional activity is also regulated by acety-
lation. The eﬀects of oxidative stress-induced acetylation on
FOXO function vary based upon the experimental condi-
tions. Sirtuins (SIRTs), mammalian homologs of the yeast
silent information regulator 2 (sir2) deacetylase, are critical
regulators of FOXO transcriptional activity and are in-
duced by oxidative stress [22, 23]. It has been reported
thatacetylationbycAMP-response-element-binding-protein
(CREB-) binding protein (CBP)/P300 positively regulates
FOXO transcriptional activity during oxidative stress, while
SIRT1-mediateddeacetylationrepressestheactivityofFOXO
transcription factors (FOXO1, FOXO3, and FOXO4) [24].
Other reports suggest that oxidative stress-induced FOXO4
acetylation negatively regulates its transcriptional activity,
and deacetylation by SIRT1 counteracts the acetylation-
mediated FOXO4 inhibition [25]. Furthermore, studies from
Brunet et al. suggest that SIRT1 diﬀerentially aﬀects FOXO3
functioninresponsetooxidativestress[23].SIRT1associates
with and deacetylates FOXO3 both in vitro and in vivo.
SIRT1 deacetylation of FOXO3 increases expression of its
target genes involved in cell cycle arrest and DNA repair
such as p27 and GADD45. In contrast, SIRT1 deacetylation
reduces expression of FOXO3 proapoptotic target genes such
Bim and Fas ligand. These results indicate that deacetylation
can both enhance and reduce FOXO3-induced activity
depending upon the target gene.
Besides phosphorylation and acetylation, FOXO proteins
are further regulated by ubiquitination during oxidative
stress. In response to insulin or growth factor signaling,
FOXO transcription factors are phosphorylated, polyubiqui-
tinated, and degraded [26]. It has been reported that AKT-
dependent phosphorylation is required as a prerequisite
for ubiquitin-mediated degradation of FOXO1 and FOXO3.
FOXO ubiquitination is mediated by F-box protein Skp2, a
subunit of the SCF (Skp1/Cul1/F-box) E3 ubiquitin ligase
protein complex [27, 28]. In contrast to insulin/growth
factor signaling, upon oxidative stress, FOXO4 becomes
monoubiquitinatedandtranslocatedintothenucleus,result-
ing in its increased transcriptional activity. Monoubiquitina-
tion of FOXO4 is mediated by E3 ubiquitin ligase murine
double minute 2 (MDM2) [28]. Figure 1(a) shows the eﬀect
of ROS-induced oxidative stress that regulates FOXO by
alteringitsphosphorylationoracetylationstatus.Incontrast,
growth factor-mediated induction of AKT which phospho-
rylates FOXO at speciﬁc amino acids leads to its export from
the nucleus and Skp2 which leads to its ubiquitination and
degradation (Figure 1(b)).
3. Role of FOXO in OxidativeStress
FOXO proteins play an important role in protection of
cells against oxidative stress. Oxidative stress is caused by
overproduction of ROS or ineﬃcient breakdown of ROS.
Eﬃcient detoxiﬁcation of ROS by cellular detoxiﬁcation
systems protects cells against oxidative damage. The levels
andenzymaticactivitiesofvariousantioxidantenzymessuch
as manganese superoxide dismutase (MnSOD), catalase, and
glutathione peroxidase are decreased during hyperglycemia-
induced oxidative stress [11]. It is now well established
that cells activate FOXO transcription factors to reduce the
level of oxidative stress by the induction of enzymes that
breakdown ROS such as MnSOD and catalase [29, 30]. For
example, FOXO3 directly binds to MnSOD promoter at
FOXObindingelementstoincreaseitsexpression.Activation
of MnSOD in mitochondria protects cells from ROS-
mediated injury by converting superoxide radicals to oxy-
gen and hydrogen peroxide (H2O2). Enzymes catalase and
glutathione peroxidase further breakdown H2O2 into water
and oxygen [30, 31]. The functional signiﬁcance of FOXO
in regulating oxidative stress is further revealed by gene
deletion studies. Mice lacking FOXO factors (FOXO 1/3/4)
in hematopoietic stem cells (HSCs) exhibit decreased self-
renewal, leading to defective repopulating activity [32]. Con-
sistent with this, FOXO-deﬁcient HSCs showed increased
ROS levels, decreased expression of antioxidant proteins,
and increased apoptosis, suggesting critical role of FOXOs in
stress resistance. Recent evidence suggests that FOXO factorsExperimental Diabetes Research 3
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Figure 1: (a) Model of FOXO regulation during ROS-induced oxidative stress. In response to ROS-induced oxidative stress, the activity
of FOXO proteins is modulated by various posttranslational modiﬁcations including phosphorylation and acetylation. The stress-activated
kinase JNK phosphorylates FOXO leading to its nuclear translocation and activation. FOXO is acetylated by acetyltransferase CBP/p300
upon oxidative stress stimuli and deacetylated by SIRT1 deacetylase. Change in the acetylation status may activate or inhibit FOXO activity
depending on the target genes and experimental conditions. Activation of FOXO by various posttranslational modiﬁcations leads to the
induction of stress response genes such as MnSOD, catalase, and GADD45α. (b) Negative regulation of FOXO by growth factor signaling.
Upon growth factor stimulation, AKT phosphorylates FOXO proteins on conserved residues, leading to their nuclear exclusion. SKP2-
dependent ubiquitination, which may be induced by Akt, leads to its subsequent degradation. P: phosphorylation; Ac: acetylation; Ub:
ubiquitination.
play a fundamental role in skeletal homeostasis by upregu-
lating antioxidant enzymes [33, 34]. Deletion of FOXO1 in
osteoblasts results in decreased expression of antioxidants
such as glutathione. The resulting increased oxidative stress
reduces osteoblast numbers and bone formation. Consistent
with this, conditional deletion of FOXO factors (FOXO
1/3/4) in bone results in increased oxidative stress, loss of
osteoblasts, and decreased bone mass, suggesting, FOXO
factors are indispensable for skeletal homeostasis because
of their antioxidant defense properties [33, 34]. It was
also found that FOXO1 deletion in osteoblasts is associated
with decreased protein synthesis. FOXO1 promotes protein
synthesis in osteoblasts through direct regulation of ATF4,
a transcription factor required of amino acid import and
protein synthesis [33]. In the previous example, FOXO1 is
protective through the induction of antioxidants. However,
under conditions where inﬂammation is high, FOXO1
may also have a direct eﬀect on osteoblasts by mediating
inﬂammation-induced apoptosis [35]. In this case, FOXO1
is thought to induce expression of proapoptotic factors and
exert an apoptotic rather than a protective eﬀect. Under
conditions of bone formation, FOXO1 may exert another
set of eﬀects. It has been reported that FOXO1 is needed
for diﬀerentiation of osteoblast precursors to osteoblasts and
that overexpression of FOXO1 interferes with progression of
osteoblast precursors through the cell cycle [36]. Thus, the
impact of FOXO1 on osteoblasts or their precursors may be
highly dependent upon the context and microenvironment.
4. Role of FOXO in Cell Proliferation
andSurvival
FOXO transcription factors play a role in cell proliferation
and survival by regulating the expression of genes involved
in a number of cellular processes including cell cycle arrest,
DNA repair, and apoptosis. In response to certain levels of
oxidative stress, FOXO factors induce expression of target
genes that control cell cycle progression and DNA repair,
including p27Kip1, retinoblastoma-like protein p130, and
cyclin D1/2, growth arrest, and DNA damage-inducible
gene 45α (GADD45α)[ 37–41]. For example, FOXO causes
cell-cycle arrest in G1 phase by inducing negative cell-
cycle regulators such as cdk inhibitor p27kip1 [37]a n db y
repressing the expression of G1 cyclins D1 and D2 [40].
Besides promoting cell cycle arrest, FOXO also plays a critical
role in stress resistance by facilitating repair of damaged
DNA. FOXO3 induces cell cycle arrest at G2-M checkpoint
and triggers DNA repair by inducing expression of the DNA
damage response gene GADD45α [41]. Although in most
cases FOXO proteins are associated with cell cycle arrest,
in some cases FOXO proteins appear to promote cell cycle
progression.
FOXO transcription factors typically induce either cell
death by regulating proapoptotic genes but depending upon
the context can enhance survival. In response to certain ROS
levels, FOXO transcription factors switch from prosurvival
to proapoptotic signaling leading to cell death. However,4 Experimental Diabetes Research
the exact molecular mechanisms by which FOXO switches
from prosurvival to prodeath signaling remain unknown.
In diabetes, chronic hyperglycemia-induced mitochondrial
ROS stimulate various signaling pathways leading to activa-
tion of FOXO, which in turn activates several proapoptotic
factors. FOXO1 activation is elevated in diabetic connective
tissue and mediates advanced glycation endproduct and
TNF-alpha-induced apoptosis both of which are elevated
in diabetic connective tissue [42–44]. It has been proposed
that diabetes-enhanced activation of FOXO1 limits wound
healing by enhancing ﬁbroblast apoptosis and proliferation
[43]. FOXO1 regulates genes of both the extrinsic and intrin-
sic apoptotic pathways [42]. FOXO3 and FOXO4 induce
apoptosis by directly binding Bcl-6 promoter and enhancing
its expression and negatively regulate expression of an
antiapoptotic protein BCL-XL [45]. It was further shown
that silencing endogenous FOXO3 or overexpression of a
dominant negative mutant of FOXO3 resulted in decreased
expression of a variety of proapoptotic genes, including
Bcl-6 and Bim, in response to hydrogen peroxide-induced
oxidative stress. We have recently shown that hyperglycemia
during diabetes stimulates microvascular endothelial cell
and pericyte apoptosis leading to early stages of diabetic
retinopathy [46]. High glucose leads to ROS generation
that enhances FOXO1 activation and induction of several
classes of genes that regulate endothelial cell behavior
including proapoptotic and proinﬂammatory factors. These
results suggest that FOXO1 plays an important role in the
development of diabetic retinopathy due to its eﬀect on
inﬂammatory and apoptotic gene expression in microvas-
cular cells [46]. Moreover, high glucose and advanced
glycation endproducts that are elevated in diabetes stimulate
loss of microvascular retinal pericytes through a process
that involves activation of FOXO1 [46, 47]. In the latter,
advanced glycation endproducts activate FOXO1 in pericytes
through the MAP kinase pathway, and the loss of pericytes is
countered by activation of Akt and NF-kappaB [47].
5.FOXOinDiabetes-InducedInﬂammation
Inﬂammationhaslongbeenconsideredasamajorriskfactor
indiabetesandassociatedwithdevelopmentandprogression
of diabetic complications. Hyperglycemia-induced oxidative
stress promotes inﬂammation through increased endothe-
lial cell damage, microvascular permeability, and increased
release of proinﬂammatory cytokines, including TNF-α,
interlukin-1β (IL-1β), and interlukin-6 (IL-6), ultimately
leading to decreased insulin sensitivity and diabetic compli-
cations. Hyperglycemia-induced FOXO plays an important
role in the induction of proinﬂammatory cytokines. It was
shown that FOXO1 directly binds to IL-1β promoter and
increases its expression in macrophages [48]. FOXO1 is
induced by inﬂammatory cytokines and may be involved in a
forward ampliﬁcation loop. For example, in microvascular
endothelial cells, FOXO1 is induced in vivo by diabetes-
enhancedTNF-αandalsoinducesexpressionofTNF-αlevels
in these cells [46]. Increased IL-1β and TNF-α production
has been implicated in pathogenesis of obesity and diabetes.
Hyperglycemia in diabetes also stimulates toll-like receptor
(TLR) signaling, which results in prolonged inﬂammation
and tissue damage. Recent studies show that FOXO1 pro-
motes inﬂammation during diabetes by enhancing TLR4-
mediated signaling, suggesting FOXO1 as a key mediator of
inﬂammatory responses during obesity and diabetes [49].
In diabetic fracture healing, there is enhanced upregulation
of proinﬂammatory and proapoptotic factors [50, 51]. It
has been shown that FOXO1 induces expression of both
proinﬂammatory and proapoptotic factors in chondrocytes
and that FOXO1 directly binds to the TNF-α promoter.
Moreover, diabetes-enhanced TNF-α activates FOXO1 in
chondrocytes in vivo by enhancing its nuclear localization
[50].
Another transcription factor that plays an important
role in stimulating inﬂammation during hyperglycemia
and oxidative stress is NF-κB[ 52]. Activation of NF-κB
pathway has been implicated in the development of diabetic
complications, including retinopathy, and has been shown
toregulateexpressionofvariousproinﬂammatorycytokines,
including TNF-α and IL-1β [53]. Chronically elevated ROS
levels associated with diabetes may induce both NF-κB
and FOXO leading to increased inﬂammation and cellular
damage. In most cell types, NF-κB is directly antiapoptotic,
whileFOXO1isdirectlyproapoptotic.Thus,ininﬂammatory
conditions when both NF-κB and FOXO1 are activated, their
relative balance may determine whether a cell ultimately
survives or undergoes apoptosis [42, 47].
5.1.Mitochondria,ROS,andDiabetes. Amechanismthrough
which diabetes can increase oxidative stress involves electron
transport in mitochondria. It has been proposed that high
intracellular glucose levels increase the follow of electrons
throughtheelectrontransportchaininmitochondriaduring
oxidative respiration [6]. This can result in the transfer
of electrons to O2 leading to formation of O2
− and the
generation of various reactive oxygen species in the mito-
chondria. Furthermore, changes caused by diabetes alter
the redox balance and aﬀect redox-sensitive proteins such
as protein kinase C-epsilon, which can result in enhanced
mitochondrial ROS production. Advanced glycation end
products (AGEs) generated under conditions of hyper-
glycemia stimulate NADPH oxidase that in turn can induce
production of ROS. In a surprising development, increased
Wnt signaling stimulates mitochondrial biogenesis that can
lead to enhanced ROS levels in mitochondria and greater
oxidative damage [54]. The increased ROS in mitochondria
is thought to be problematic due to a number of diﬀerent
mechanisms. One is that ROS damages mitochondrial
components such as DNA, membrane proteins, and lipids.
ROS can also induce the opening of the mitochondrial
permeability transition pore (MPTP) [55]. When this pore
is opened, proapoptotic proteins are released from the
mitochondria such as cytochrome c that stimulate cell death.
ROS generated in the mitochondrial respiratory chain have
beenproposedassecondarymessengersforactivationofNF-
κBb yT N F - α and IL-1 [6].
ROS may aﬀect insulin signalling. Insulin signalling is
reduced under conditions of oxidative stress, which may
contribute to insulin resistance. This may occur throughExperimental Diabetes Research 5
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Figure 2: Oxidative stress and insulin signaling aﬀect mitochondrial function via FOXO. ROS induce IRS serine phosphorylation which
inhibits IRS activation by insulin signalling. As a result of reduced IRS activity, Akt activity is reduced. Reduced Akt reduces negative
signalling of FOXO so that FOXO1 is left in an activated state since it is not exported out of the nucleus by 14-3-3. Meanwhile, ROS
activate MST1 and JNK which induce FOXO nuclear translocation by disrupting the complex of FOXO and 14-3-3. PP2A activates FOXO
by dephosphorylation of FOXO and by Akt dephosphorylation. FOXO nuclear translocation will induce HMOX1 gene expression which
inhibits mitochondrial function by aﬀecting like fatty acid oxidation, ATP, and oxidative respiration (arrow indicates stimulatory event; bar
indicates inhibitory event).
several mechanisms. In one scenario, ROS induces serine
phosphorylation of insulin receptor substrate, decreasing
tyrosine phosphorylation thereby interfering with insulin
signaling [56]. Similarly, ROS have been shown to partially
mediate the eﬀect of Angiotensin II inhibition of insulin
signalling [57]. Methylglyoxal, a biologically active AGE pre-
cursor formed under conditions of hyperglycemia, inhibits
phosphorylation of insulin receptor substrate and activation
of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B
(PKB) pathway [58].
Insulin signalling inactivates FOXO1, which is mediated
by insulin receptor substrates-1 and -2 through AKT. A
characteristic feature of insulin resistance is the elevated
production of glucose that contributes to hyperglycemia.
FOXO1 regulates glucose production in the liver through
the expression of genes that promote gluconeogenesis [59].
Thus, a pathway exists whereby insulin resistance leads
to elevated FOXO1 activation, upregulation of genes that
promote glucose production, and greater serum glucose
levels. Disruption of the insulin-Akt-FOXO1 balance also
aﬀects the mitochondria. Activated FOXO1 induces heme
oxygenase-1 (HMOX1), which cleaves heme and disrupts
the mitochondrial electron transport chain [60]. Thus,
when FOXO1 activity is elevated by insulin resistance,
greater expression of heme oxygenase-1 ensues. Greater
heme oxygenase-1 levels interfere with mitochondria leading
to impaired oxidative respiration, negatively aﬀecting fatty
acid oxidation and the production of ATP. Furthermore,
enhanced activation of FOXO1 aﬀects the expression mito-
chondrial fusion and ﬁssion thereby aﬀecting mitochondrial
biogenesis. Under conditions of insulin resistance, there
are insuﬃcient mitochondria and abnormal mitochondrial
morphology, which is reversed when FOXO1 is deleted
[60]. Figure 2 demonstrates the complex signalling pathways
through which oxidative stress and insulin can modulate
FOXO activity to aﬀect mitochondria.
6. Conclusion andPerspective
Hyperglycemia-inducedROSandsubsequentoxidativestress
are major contributors to the development and progression
of diabetes and related complications. However, eﬀective
therapeutic strategies to prevent the generation of these free
radicals remain limited. It is now well established that FOXO
transcription factors are the critical regulators of cell fate
and play a major role in diabetes-induced oxidative stress
resistance and in diabetes-enhanced apoptosis. It seems that
FOXO transcription factors might function as molecular
switches that determine cell fate in response to various levels
of oxidative stress by either promoting antioxidants (pro-
survival) responses or alternatively enhancing proapoptotic
gene expression and cell death. However, the precise mech-
anism by which FOXO mediates prosurvival/proapoptotic
response remains unclear and elucidation of molecular
mechanisms involved may provide new targets for therapy.
Furthermore, multiple signaling pathways, including JNK6 Experimental Diabetes Research
and MAPK, regulate the activity of FOXO transcription
factors in response to hyperglycemia in diabetes. Because
our understanding of how these diverse signaling pathways
coordinate their eﬀects to regulate FOXO activity during
diabetes remains limited, detailed understanding of these
pathways may provide insights into development of new
therapeutic strategies for treatment of diabetes.
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